Arca
Skip to content
Tools
Tools

ACHE, BCHE: Cholinesterases; ACHE & BCHE

Selectivity group in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ACHE, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Rivastigmine
  • Tacrine

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        RivastigmineApprovedAB ScienceSmall moleculeInhibitorCholinesterases; ACHE & BCHE inhibitor8
        TacrineApprovedShionogiSmall moleculeInhibitorCholinesterases; ACHE & BCHE inhibitor1

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
        Comparing Dual-mobility Cups Versus Unipolar Cups for Unselected Primary Total Hip Arthroplasty by Direct Anterior ApproachTacrineNot applicableRecruitingElsanMar 11, 2026
        Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's DiseaseRivastigmineEarly phase 1RecruitingAnhui Provincial HospitalOct 6, 2025
        Rivastigmine Mini-Tablet for Alzheimer's DiseaseRivastigmine—Not yet recruitingPeking University First HospitalFeb 14, 2025
        A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's DiseaseRivastigminePhase 3RecruitingI.R.C.C.S. Fondazione Santa LuciaNov 22, 2024
        Rivastigmine for Antimuscarinic DeliriumRivastigminePhase 2RecruitingWashington University School of MedicineApr 24, 2024
        Masitinib in Patients With Mild Alzheimer's DiseaseRivastigminePhase 3Not yet recruitingAB ScienceOct 3, 2022
        Toward a Computationally-Informed, Personalized Treatment for HallucinationsRivastigmineEarly phase 1RecruitingYale UniversityApr 29, 2020
        Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)RivastigminePhase 4Not yet recruitingUniversity Hospital, BordeauxMar 6, 2018
        Quality Improvement and Practice Based Research in Neurology Using the EMRRivastigminePhase 4Enrolling by invitationEndeavor HealthFeb 1, 2016

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095233, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.